BCL6 is a zinc-finger transcriptional repressor known for its oncogenic role in B cell lymphoma. In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph + acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors.
The Philadelphia chromosome-positive (Ph + ) leukemias, chronic myeloid leukemia (CML), and Ph + B cell acute lymphoblastic leukemia (B-ALL) are prevalent blood cancers that comprise about a quarter of all leukemias in adults. The product of the Ph chromosome, BCR-ABL1, is a dysregulated protein-tyrosine kinase that is the direct cause of both forms of leukemia, as ectopic expression of BCR-ABL1 in the relevant bone marrow target cells leads to phenotypically identical neoplasms in mice (Hu et al., 2006) . In CML patients in the chronic phase of their disease, treatment with any one of the three BCR-ABL1 tyrosine kinase inhibitors (TKIs) approved by the United States Food and Drug Administration (imatinib, dasatinib, or nilotinib) is remarkably effective, with the great majority of patients achieving sustained cytogenetic remissions. Unfortunately, the outcome of TKI therapy in Ph + B-ALL is not nearly as favorable, with most patients relapsing quickly after transient decreases in the burden of their leukemia (Druker et al., 2001) . Although TKIs are being incorporated into chemotherapy regimens for treatment of Ph + B-ALL, the best chance for long-term survival for such patients is to undergo allogeneic hematopoietic stem cell transplantation, a risky and costly procedure. The mechanism of selective killing of BCR-ABL1-expressing leukemic cells by ABL1-specific TKIs is not completely understood, but upregulation of proapoptotic pathways may contribute, as leukemias induced by BCR-ABL1 in bone marrow cells from mice lacking p53 (Wendel et al., 2006) or Bim (Kuroda et al., 2006) are relatively resistant to imatinib. The reasons for relapse of Ph + B-ALL following TKI therapy are also murky. While some recurrences can be ascribed to amplification of the BCR-ABL1 fusion gene or to BCR-ABL1 kinase domain mutations that render the enzyme resistant to the TKI (Gorre et al., 2001) , the majority of treatment failures are blamed on the inability of the drug to eliminate the so-called leukemia stem cells, defined rigorously as clonogenic leukemic cells capable of recapitulating the disease upon transplantation. Studies in syngeneic mouse models (Hu et al., 2006) and from xenotransplantation of human B-ALL into immunodeficient mouse recipients (Castor et al., 2005) In a study published in a recent issue of Nature, Markus Mü schen and colleagues, via an elegant and sophisticated set of experiments, implicate BCL6 as a key element of a transcriptional network in BCR-ABL1-expressing B-ALL cells that controls the cell cycle and apoptotic responses to TKI treatment (Duy et al., 2011) . exhibited an altered cellular response to BCR-ABL1 inhibition with increased p53 expression and apoptosis, whereas Bcl6 +/+ lymphoblasts had a more restrained induction of p53 and exited the cell cycle to become quiescent. These findings were reproduced in primary human Ph + B-ALL samples transduced with a dominantnegative BCL6 mutant. Together, these results suggest a model wherein tonic repression of BCL6 increases the leukemogenicity of BCR-ABL1-transformed B-lymphoid progenitors, whereas induction of BCL6 tends to counteract TKI-induced apoptosis through repression of p53 and ARF (Figure 1 ). How might these new findings be translated to the clinic? In drug development, targeting transcription factors (at least those that lack natural ligands such as nuclear hormone receptors) has proven notoriously difficult. In this work, the authors turned to a novel peptidomimetic inhibitor of BCL6, RI-BPI, which binds to BCL6 and blocks its ability to recruit corepressor proteins. RI-BPI increased the sensitivity of BCR-ABL1 + B-ALL cells to imatinib to a similar extent as BCL6 (Chan et al., 2011; O'Hare et al., 2009 ) is warranted. Massively parallel sequencing enables the sequencing of whole genomes, exomes, and transcriptomes from many tumor samples. Thus, it now is possible to comprehensively identify somatic mutations, including single base changes, deletions, insertions, and genomic rearrangements. Early results for hematopoietic tumors show great promise, but many questions remain to be answered.
Improved methods for sequencing the human genome at an increasingly lower cost are now being applied to all kinds of tumors (Lander, 2011) . A recent paper in Nature (Puente et al., 2011) offers a glimpse of the power of integrating genomic technologies, including global sequence analysis, in B cell chronic lymphocytic leukemia (CLL). Genomic analysis started from an in-depth analysis of four patients representing the two major molecular subtypes of CLL: two with and two without somatic hypermutation of the immunoglobulin heavy chain variable region (IGHV). Paired advanced tumor and normal blood cells isolated before and after treatment, respectively, were studied using multiple independent technologies: whole genome sequencing (WGS); mate pair sequencing of 2.5 kb DNA fragments for efficient detection of DNA rearrangements; and chip analyses for single nucleotide polymorphisms (SNPs), DNA copy number, and RNA expression. This allowed the authors to determine that the sequencing identified 99.4% of the heterozygous SNPs. Importantly, for a subset of the putative somatic mutations, they were able to validate 96% by Sanger sequencing. They found approximately 1000 somatic substitutions per CLL genome. The pattern of base changes and dinucleotide context differed for the IGHV-mutated and IGHVunmutated tumors. The authors suggested that the higher frequency of A > T and C > G transversions in the IGHVmutated cases was consistent with their introduction by the error prone-polymerase h during somatic hypermutation in immunoglobulin genes. Altogether, they identified changes in the proteincoding region of 45 genes in the four tumors, including 41 nonsynonymous single base substitutions and 5 insertions/deletions (indels). Typically, CLL have only a limited number of genomic rearrangements. The comprehensive mate pair analyses enabled the authors to identify and characterize ten large genomic alterations, six of which-including large 13q14 deletions in three tumors-have been reported previously in CLL.
Focusing on the 26 mutated, expressed genes, Puente et al. (2011) then extended these findings to a cohort of 169 CLL patients. Using a clever pooled-sequencing strategy, they determined that other CLL tumors had mutations, suggesting identification of four driver genes: NOTCH1, 12.2%; MYD88, 2.9%; XPO, 2.4%; and KLHL6, 1.8%. The nonsynonymous to synonymous mutation ratio in the remaining 22 expressed genes and the 19 unexpressed genes were 2.83 and 2.71, respectively, consistent with the lack of selection expected if most are passenger genes (Chapman et al., 2011) .
Of the NOTCH1 mutations, which occurred in 20% of IGHV-unmutated and 7% of IGHV-mutated CLL, 29/31 were the P2515Rfs*4. This mutation previously had been identified in lymphoid malignancies, including T cell acute lymphoblastic leukemia and B-CLL. The P2515Rfs*4 mutation and the other two NOTCH 1 mutations all generate premature stop codons predicted to result in truncated proteins lacking the destabilizing PEST domain. The authors confirmed that leukemias carrying the NOTCH1 P2515Rfs*4 mutation expressed higher levels of truncated NOTCH1, together with higher levels of NOTCH1 target genes. In addition, the NOTCH1 mutation is correlated with a more advanced clinical stage at diagnosis, a shorter survival, and an increased frequency of transformation into diffuse large B cell lymphoma (DLBCL). All of the MYD88 mutations, Cancer Cell 20, July 12, 2011 ª2011 Elsevier Inc. 5
